What you are currently seeing is the LTP share price suffering as a result of the Opthea (OPT) failure.
Regal funds management are a substantial shareholder and putting selling pressure on other ASX biotech's at the moment (evidenced today and yesterday) - broker activity data will confirm this.
PRE IND meeting on it's way (company has flagged Q1 2025). Any guidance/direction from the FDA here will be interesting.
What's been happening with this stock in the last 6 months: Minimal/limited announcements, low liquidity, lack of buyers, large placement to institutions (who are now most likely exerting selling pressure on the stock).
I want to see this FDA guidance after the PRE IND meeting.
LTP Price at posting:
49.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)